HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fink-Bennett, D. M. Articles by Thomas, K. Search for Related Content PubMed PubMed Citation Articles by Fink-Bennett, D. M. Articles by Thomas, K.

⁹⁰Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma*

¹Department of Nuclear Medicine, William Beaumont Hospital, Royal Oak, Michigan;
²Department of Nuclear Medicine, City of Hope National Medical Center, Duarte, California

View larger version (41K): [in a new window]   FIGURE 1. Components of 90Y-ibritumomab tiuxetan.

View larger version (67K): [in a new window]   FIGURE 2. Radioimmunotherapy uses targeting of monoclonal antibody to produce crossfire effect with radioimmunoconjugate.

View larger version (13K): [in a new window]   FIGURE 3. Imaging and therapy protocol is administered over 7–9 d.

View larger version (66K): [in a new window]   FIGURE 4. Serial whole-body anterior gamma camera images after injection of 111In-ibritumomab tiuxetan illustrate normal biodistribution, including blood pool (diminishes over time), liver, spleen, and bulky tumor. Abdominal SPECT and CT views correlate uptake with abdominal adenopathy.